ASCENTAGE PHARMA GROUP-B (06855) announced that Dr. Debra Yu will be appointed as an additional member of the Board Nomination Committee, effective December 26, 2025. Dr. David Sidransky will be appointed as the Lead Independent Non-Executive Director, effective December 26, 2025, to serve (i) as an intermediary between other directors and the company's shareholders; and (ii) as a point of contact for other directors and the company's shareholders when normal communication channels with the Board Chairman or the company's management are insufficient. A Board R&D Committee will be established, effective December 26, 2025. The R&D Committee will be composed of scientists, physicians, and business experts, responsible for overseeing R&D strategy, product pipeline, investments, and emerging trends, while managing risks and ensuring alignment with business objectives. The R&D Committee will be chaired by Dr. Marc E. Lippman, MD, with Dr. David Sidransky and Dr. Shaomeng Wang serving as members.